Following an expert call with Dr. Stanley Jordan from Cedars-Sinai, Piper Jaffray analyst William Quirk says CareDx remains a top small cap pick with an Overweight rating and $63 price target. Jordan spoke highly of AlloSure and said it has been a helpful test to identify kidney transplant rejections early and avoid unnecessary biopsies, Quirk tells investors in a research note. Further, the doctor was confident test utility will expand with more research, adds the analyst. Quirk remains confident in CareDx's position in the kidney transplant market.